Intra-arterial instillation of microencapsulated, ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting

Kröger, Jürgen; Benz, Stefan; Hoffmeyer, Anne; Bago, Zoltan Tibor; Bergmeister, Helga; Günzburg, Walter H.; Karle, Peter; Klöppel, Günter; Losert, Udo; Müller, Petra; Nizze, H; Obermaier, Robert; Probst, Alexander J.; Renner, Matthias; Saller, Robert; Salmons, Brian; Schwendenwein, Ilse; Rombs, Kerstin von; Wiessner, Reiko; Wagner, Thomas; Hauenstein, Karlheinz; Löhr, Matthias

doi:10.1159/000069147

Cited by 12 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histological sections of material resected from the tumour and surrounding areas showed that the encapsulated cells were well tolerated, with no or only mild immune reactions. These findings are in line with those from previous studies, both from a clinical phase I/II trial for pancreatic cancer in human patients [16], [31], [32], as well as in animal models [14], [15], [19], [33]. In this respect, it is worth mentioning that even encapsulated hybridoma cells producing a monoclonal antibody [34], [35] or encapsulated retroviral vector producing cells [36] have been shown to be well tolerated after implantation into immunocompetent mice.…”

Section: Discussionsupporting

confidence: 90%

Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours

et al. 2014

Self Cite

View full text Add to dashboard Cite

Based upon promising preclinical studies, a clinical trial was performed in which encapsulated cells overexpressing cytochrome P450 enzyme isoform 2B1 were implanted around malignant mammary tumours arising spontaneously in dogs. The dogs were then given cyclophosphamide, one of the standard chemotherapeutic agents used for the treatment of mammary tumours. The dogs were assessed for a number of clinical parameters as well as for reduction in tumour size. The treatment was well tolerated with no evidence of adverse reactions or side effects being associated with the administration of the encapsulated cells. Reductions in tumour size of more than 50% were observed for 6 out of the 11 tumours analysed while 5 tumours showing minor responses, i.e. stable disease. In contrast, the tumours that received cyclophosphamide alone showed only stable disease. Taken together, this data suggests that encapsulated cytochrome P450 expressing cells combined with chemotherapy may be useful in the local treatment of a number of dog mammary tumours and support the performance of further clinical studies to evaluate this new treatment.

show abstract

Section: Discussionsupporting

confidence: 90%

Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…[26] Cellulose sulfate capsules seem to provoke little immune response [27] and almost no foreign body reactions. [28,29] Another hitherto unsolved issue is the quality control of the encapsulated cells in terms of viability and production of therapeutic proteins. With both alginate and cellulose sulfate, encapsulation is facilitated by mixing the encapsulation material with the cells and then letting them drop through a nozzle into a precipitation bath.…”

Section: Encapsulation Materialsmentioning

confidence: 99%

“…Following experimental studies [28] and feasibility studies, [29] a phase I/II study was conducted in patients with pancreatic carcinoma using a GDEPT with the cytotoxic prodrug ifosfamide and its converting enzyme CYP2B1. [52] Encapsulated CYP2B1-producing cells were delivered angiographically toward the tumor and patients were treated with low-dose ifosfamide.…”

Section: Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Therapy with Cell Encapsulation for Substitution of Organ Function and Tumor Treatment

et al. 2009

View full text Add to dashboard Cite

Cell encapsulation represents an innovative technique. However, clinical applications are sparse. Most experiments and clinical studies have been performed with either alginate or cellulose sulfate capsules, containing several cell lines and a broad variety of applications, ranging all the way from substitution for impaired organ function and release of cytokines or growth factors to gene‐directed enzyme prodrug therapy. A few clinical studies have been conducted and/or are under way.

show abstract

“…In oncology, precise intra‐lesion delivery offers potential improvements in efficacy and safety of chemotherapeutics and other emerging cell‐based cancer treatments. Immune‐based treatments, such as CAR‐T cells and chemotherapy‐activating cells , could be injected directly into the tumour, potentially increasing efficacy whilst keeping systemic and organ side effects of the treatments to a minimum.…”

Section: Introductionmentioning

confidence: 99%

Superselective endovascular tissue access using trans‐vessel wall technique: feasibility study for treatment applications in heart, pancreas and kidney in swine

et al. 2018

View full text Add to dashboard Cite

show abstract

Intra-arterial instillation of microencapsulated, ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting

Cited by 12 publications

References 23 publications

Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours

Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours

Therapy with Cell Encapsulation for Substitution of Organ Function and Tumor Treatment

Superselective endovascular tissue access using trans‐vessel wall technique: feasibility study for treatment applications in heart, pancreas and kidney in swine

Contact Info

Product

Resources

About